Q2 2026 ANI Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2026 / 12:00 PM GMT

Release Date Price: €66 (-2.94%)

Transcript 10-Q8-K

Key Points

Positve

Record Q2 2026 revenues of $266 million, up 26% year-over-year, driven by strong performance in rare disease and generics.
Record Cortrophin Gel revenues of $117.1 million, up 43% year-over-year and 56% sequentially, with continued momentum in existing specialties.
Record adjusted EBITDA of $71.6 million, up 32% year-over-year, exceeding prior expectations.
Successful execution of the largest rare disease sales force expansion, increasing headcount by 50% to ~180 reps, with strong early demand from the gout launch (95% of new reps generated multiple new cases).
Generics business delivered $99.1 million in Q2, up 10% year-over-year, with 12 product launches in 2026 and a strong pipeline.
Healthy balance sheet with $360.2 million in cash and net leverage of 1.0x, providing capacity for future M&A.
Reaffirmed full-year 2026 guidance for total revenue ($1.08B-$1.14B) and adjusted EBITDA ($285M-$300M), reflecting 26% and 27% growth, respectively.
Cortrophin Gel guidance revised to $520M-$540M, still representing 50-55% growth over 2025, with back-half expectations largely intact.
Strong demand indicators for gout expansion: over 95% of new reps have multiple new cases, and over a third of prescribers have initiated 2+ cases.
Positive early results from the Phase 4 synchronicity trial for Eluvian, with detailed data to be presented in Q4 2026.

Negative

Cortrophin Gel full-year guidance was modestly revised downward to $520M-$540M, primarily due to first-half results, which were below initial expectations.
Eluvian revenues declined 16% year-over-year in Q2 to $18.7 million, due to timing of international shipments.
Non-GAAP gross margin decreased 230 basis points to 62.6% in Q2, driven by product mix.
SG&A expenses increased 20% year-over-year to $80.7 million, driven by the gout expansion and higher support costs.
Q3 2026 adjusted EBITDA is expected to be down sequentially due to the first fully loaded quarter of gout expansion expenses and lower Harmony milestone revenue.
The company faced insurance re-verification issues in Q1 that impacted volumes, and while resolved, some patients were permanently lost.
Gout expansion had limited revenue impact in Q2, with meaningful contribution only expected in Q3 and Q4, creating execution risk.
The company did not provide specific metrics on gout flare treatments or revenue per patient, limiting visibility into the launch's early performance.
IQVIA data shows a disconnect with reported revenues, raising concerns about script-to-revenue conversion.
The company faces potential competitive pressures and gross-to-net dynamics, though no specific issues were disclosed.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ANIP.OQ - ANI Pharmaceuticals, Inc.
Q2 2026 ANI Pharmaceuticals Inc Earnings Call
Aug 07, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Into today's Anti Pharmaceuticals Inc.

Second quarter, 2026 earnings results call.

Please note this call is being recorded.

After the speaker's prepared remarks, there will be a question-and-answer session.

If you would like to ask a question during this time, simply press star, then 11 on your telephone keypad.

If you would like to withdraw your question, please press the star key, then 11, again on your telephone keypad.

It is now my pleasure to turn the conference over to Irina Kopfler, please go ahead.

Thank you, Danielle.

Welcome to ANI Pharmaceuticals second quarter 2026 earnings results call.

This is Irena Kopfler, investor

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.